Vincerx Pharma Inc (NASDAQ: VINC) has seen a decline in its stock price by -38.29 in relation to its previous close of 0.28. However, the company has experienced a -38.43% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-17 that Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Is It Worth Investing in Vincerx Pharma Inc (NASDAQ: VINC) Right Now?
Moreover, the 36-month beta value for VINC is 1.58. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VINC is 4.49M and currently, short sellers hold a 3.06% of that float. On April 21, 2025, VINC’s average trading volume was 1.15M shares.
VINC’s Market Performance
VINC stock saw a decrease of -38.43% in the past week, with a monthly decline of -76.40% and a quarterly a decrease of -94.44%. The volatility ratio for the week is 18.11%, and the volatility levels for the last 30 days are 18.74% for Vincerx Pharma Inc (VINC). The simple moving average for the last 20 days is -65.20% for VINC stock, with a simple moving average of -97.58% for the last 200 days.
Analysts’ Opinion of VINC
Many brokerage firms have already submitted their reports for VINC stocks, with H.C. Wainwright repeating the rating for VINC by listing it as a “Buy.” The predicted price for VINC in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on January 14, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VINC reach a price target of $25. The rating they have provided for VINC stocks is “Overweight” according to the report published on December 23rd, 2021.
SVB Leerink gave a rating of “Outperform” to VINC, setting the target price at $24 in the report published on November 01st of the previous year.
VINC Trading at -79.61% from the 50-Day Moving Average
After a stumble in the market that brought VINC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.15% of loss for the given period.
Volatility was left at 18.74%, however, over the last 30 days, the volatility rate increased by 18.11%, as shares sank -73.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -88.17% lower at present.
During the last 5 trading sessions, VINC fell by -38.61%, which changed the moving average for the period of 200-days by -98.96% in comparison to the 20-day moving average, which settled at $0.4875. In addition, Vincerx Pharma Inc saw -96.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VINC
The total capital return value is set at -11.55. Equity return is now at value -431.29, with -229.38 for asset returns.
Currently, EBITDA for the company is -31.46 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
To wrap up, the performance of Vincerx Pharma Inc (VINC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
